Live Breaking News & Updates on Duration Of Therapy

Stay updated with breaking news from Duration of therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings. ....

United States , Vaishali Sanchorawala , Heather Landau , Jeffrey Zonder , Peer Exchange , American Society Of Hematology , American Society , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis. ....

Vaishali Sanchorawala , Jeffrey Zonder , Heather Landau , Peer Exchange , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis. ....

United States , Vaishali Sanchorawala , Heather Landau , Jeffrey Zonder , Peer Exchange , American Society Of Hematology , American Society , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

The Potential Role of CAR T Therapy in AL Amyloidosis

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis. ....

Heather Landau , Jeffrey Zonder , Vaishali Sanchorawala , Peer Exchange , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,

Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study. ....

Transforming Outcomes , Precision Medicine , Targeted Therapies , Treatment Approaches , Abs Targeting Amyloid Deposits , Light Chain Amyloidosis , Al Amyloidosis , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Duration Of Therapy , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis ,